Share price · HELP
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when HELP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 16 Nov 2026-13.5%
- 2 Nov 2026-16.9%
Nothing announced by HELP that day or the session before.
- 9 Sep 2026+10.4%
- 12 Aug 2026+13.9%
- Day beforeCybin: 6-K filing
- 10 Aug 2026-13.8%
Nothing announced by HELP that day or the session before.
- 5 Aug 2026+13.5%
Nothing announced by HELP that day or the session before.
- 4 Aug 2026+15.1%
- Day beforeCybin: 6-K filing
- 21 Jul 2026+13.9%
- 16 Jul 2026+8.1%
- 25 Jun 2026+18.3%
Share of unusual movement by asset
For each asset, the share of HELP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Deupsilocinevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 49% |
| Sessions with no dated event | — | 50% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | 5-HT2A receptorSmall molecule | Major Depressive Disorder |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Insider transactions
Open-market activity, trailing 12 months: 9 purchases ($9.7M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-30 | Glavine Paul · director, Chief Growth Officer | Award / grant | 248,000 | — | — | Form 4 |
| 2026-09-30 | So Eric H. L. · director | Award / grant | 248,000 | — | — | Form 4 |
| 2026-09-29 | Cavers Greg · Chief Financial Officer | Open-market purchase | 3,000 | $12.91 | $39K | Form 4 |
| 2026-09-21 | Halstead Michael · Chief Executive Officer | Open-market purchase | 100,000 | $13.47 | $1.3M | Form 4 |
| 2026-09-08 | So Eric H. L. · director, Executive Chair | Open-market purchase | 100,000 | $12.39 | $1.2M | Form 4 |
| 2026-09-08 | Glavine Paul · Chief Growth Officer | Open-market purchase | 100,000 | $12.47 | $1.2M | Form 4 |
| 2026-09-08 | Glavine Paul · Chief Growth Officer | Open-market purchase | 100,000 | $12.47 | $1.2M | Form 4 |
| 2026-09-04 | So Eric H. L. · director, Executive Chair | Open-market purchase | 100,000 | $12.09 | $1.2M | Form 4 |